News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ranbaxy Pharmaceuticals Inc.'s Lipitor Copy Threatens Pfizer Inc. (PFE) Sales


12/1/2011 9:11:03 AM

Ranbaxy Laboratories Ltd. (RBXY) won approval to sell generic copies of the $10.7 billion cholesterol pill Lipitor in the U.S., threatening Pfizer Inc. (PFE)’s sales. U.S. Food and Drug Administration clearance for Ranbaxy, India’s biggest drugmaker, followed a dispute over whether the company could produce the copies given questions about its manufacturing plants. A deal to share profits with Teva Pharmaceutical Industries Ltd. (TEVA), a generic-drug maker based in Israel, helped overcome that hurdle.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES